Loading patent…
AssigneeThe Universify of North Carolina at Chapel Hill
InventorsMonica Schmidt, Michael Fried
Estimating the term…
Methods of determining the presence or risk of liver disease or other diseases in a subject include measuring a level of a saccharide selected from N-acetylneuraminic acid, N-acetylglucosamine, N-acetylgalactosamine, or a combination thereof on one or more glycosylated proteins and the total amount of alpha-fetoprotein in a biological sample from the subject. Glycosylated proteins include but are not limited to vascular endothelial growth factor, lymphatic vessel endothelial hyaluronan receptor, E-cadherin, alpha 1 acid glycoprotein, glypican-3, galectin-3, and any combination thereof. The presence or risk of disease in the subject is determined responsive to a value based on the level of glycosylation and amount of alpha-fetoprotein.
A method for detecting the presence of a liver disease in a subject, comprising:
3-7. (canceled)
A method for staging a liver disease in a subject, comprising:
10-13. (canceled)
18-19. (canceled)
21-23. (canceled)
30-32. (canceled)
35-39. (canceled)
42-49. (canceled)
51-66. (canceled)
Dependencies are inferred from the claim text.